News & Updates

Show Multimedia Only
Multimodal strategies needed to halt progression of MCI and Alzheimer’s disease
Multimodal strategies needed to halt progression of MCI and Alzheimer’s disease
04 Jun 2026
Donanemab delays Alzheimer's disease progression over 3 years
Donanemab delays Alzheimer's disease progression over 3 years
04 Jun 2026 byKanas Chan

Donanemab administered for a limited duration continues to slow clinical progression in patients with early symptomatic Alzheimer’s disease (AD) over 3 years, according to Professor Chaur-Jong Hu of the Department of Neurology, Taipei Medical University, who spoke at Advances in Medicine (AIM) 2026. 

Donanemab delays Alzheimer's disease progression over 3 years
04 Jun 2026